This company is no longer active
IMNP.Q Stock Overview
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Immune Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0022 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0 |
| 1 Month Change | -35.94% |
| 3 Month Change | -44.75% |
| 1 Year Change | -68.43% |
| 3 Year Change | -99.92% |
| 5 Year Change | -100.00% |
| Change since IPO | n/a |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IMNP.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -33.0% | -4.7% | -3.7% |
| 1Y | -68.4% | -2.7% | 20.2% |
Return vs Industry: IMNP.Q underperformed the US Biotechs industry which returned -1.1% over the past year.
Return vs Market: IMNP.Q underperformed the US Market which returned -13.6% over the past year.
Price Volatility
| IMNP.Q volatility | |
|---|---|
| IMNP.Q Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMNP.Q's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IMNP.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Gary Rabin | www.immunepharma.com |
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company’s lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis.
Immune Pharmaceuticals, Inc. Fundamentals Summary
| IMNP.Q fundamental statistics | |
|---|---|
| Market cap | US$401.99k |
| Earnings (TTM) | -US$34.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IMNP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMNP.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$34.39m |
| Earnings | -US$34.39m |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IMNP.Q perform over the long term?
See historical performance and comparison